Please wait while you are redirected to the right page...
Please share your location to continue
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our privacy policy.
![Atomic models proposed for the L-hammerhead ribozyme and the L-DNAzyme interacting with their target D-RNA. [Volker A. Erdmann et al.]](https://www.genengnews.com/wp-content/uploads/2018/08/MirrorImageZymes_FreeUniOfBerlin1071156617-324x160.jpg "Looking-Glass Nucleic Acid Zymes Promise RNA-Editing Wonderland")
![Cardiomyocytes (shown in green) proliferating in a mouse heart after gel injection. [University of Pennsylvania]](https://www.genengnews.com/wp-content/uploads/2018/08/Nov30_2017_UnivPenn_cardiomyocytes8911058981-265x198.jpg "microRNA Gel Helps Damaged Hearts Get to a Better Beat")
![RIBOTAC conjugates could offer new approach to destroying toxic gene products and treating genetic diseases. [The Scripps Research Institute]](https://www.genengnews.com/wp-content/uploads/2018/08/May30_2018_TheScrippsResearchInst_MatthewDisneyInLab1948183243-265x198.jpg "Small-Molecule RNA-Targeting Technology Kills Cancer Cells")
![Collaboration gives Servier ex-U.S./Japan global rights to three of Miragen’s preclinical programs.[© Dario Bajurin - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Oct18_2011_3203632_BloodVessels_ServierMiragenCardioDeal1671558221-265x198.jpg "Servier and miRagen Sign $352M Deal for Cardiovascular miRNA Therapeutics")
